Prospective Investigation of Multiple Sclerosis in the Three Rivers Region

Our recent study examining the cost of treatments just got published.
https://link.springer.com/article/10.1007/s40120-022-00358-4

https://twitter.com/Neurology_Ther/status/1528768357826285569

Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019 - Neurology and Therapy Introduction Comparisons of healthcare utilization and expenditure among multiple sclerosis (MS) disease-modifying therapies (DMTs) are limited. Methods In this retrospective cohort study using commercial insurance claims data of a US population (2010–2019), we compared healthcare utilization and ...

Prospective Investigation of Multiple Sclerosis in the Three Rivers Region updated their address.

In this observational cohort study of 1621 secondary progressive multiple sclerosis (SPMS) patients, researchers examined the association of relapse activity and immune disease-modifying treatments (DMT) with the rate of disability accumulation and wheelchair dependency. Higher relapse rate during the SPMS phase was associated with faster rate of disability accumulation. DMT for patients experiencing relapse during SPMS slowed the rate of disability accumulation and wheelchair dependency.

The concept of "active" SPMS is misleading, as it probably represents just the late stage of relapsing MS. Thus, it is not surprising that DMT for relapsing MS, including the late stage, reduces disability accumulation.

https://jamanetwork.com/journals/jamaneurology/article-abstract/2768700?casa_token=54Z-yegMo0oAAAAA:ULwJ8mv-OPABwSwXWiPk3XrK-KRg7lm_qfxai6RAIvHZgpObR5_706jw5N8u6M4QM0dmRl_yoBBe

Sustained Immunotherapy and Disability Accumulation in Secondary Progressive Multiple Sclerosis This cohort study uses data from the MSBase international registry to examine the association of demographic and clinical factors, including the presence of relapses and exposure to immunotherapy, with the rate of disability accumulation in patients with secondary progressive multiple sclerosis.

The National Multiple Sclerosis Society is dedicated to creating a world free of MS, but they can't do it without our help. It’s faster and easier than ever to support this cause. Your donation will drive groundbreaking research, provide life-changing services and guarantee a supportive community for those who need it most. Please visit Team: UPMC MS CHAMPIONS fundraising page to join our team or make a donation. By joining our team, you will be signing up for a great event and an important cause. Each mile we walk, each dollar we raise brings us that much closer to our goal – an end to MS.

Together, we will end MS. Simply click the link below to visit our page and make a donation.

https://secure.nationalmssociety.org/site/TR?fr_id=31744&pg=team&team_id=629269

WALK MS® Walk MS connects people living with MS and those who care about them.

Sphingosine-1-phosphate receptor (S1P1R) is a promising target for immunomodulation in MS. The first S1P1R modulator, Fingolimod, received approval in 2010 for treatment of relapsing type of multiple sclerosis (MS). To address the side effect profile of fingolimod, there has been development of several selective S1P1R receptor modulators. Ponesimod is an oral selective S1P1R modulator that induces a rapid, dose-dependent, and reversible sequestration of lymphocytes in lymphoid organs. This phase 3 multicenter, double-blind randomized clinical trial compared ponesimod (20mg daily, n=567) to teriflunomide (14mg daily n=566), a pyrimidine synthesis inhibitor previously approved for relapsing MS. Randomization was stratified by use of MS disease modifying therapy in the 2 years prior (presence or absence) and baseline Expanded Disability Status Scale score (≤3.5 or >3.5). Ponesimod reduced the annualized relapse rate (30.5%), brain volume loss (0.34%), focal active inflammatory disease activity (56%) and fatigue (mean difference -3.57 on Fatigue Symptom and Impact Questionnaire–Relapsing Multiple Sclerosis), while the proportion of patients achieving the status of no evidence of disease activity was greater for ponesimod (25% v. 16%). There was no difference in time to confirmed disability accumulation. The side effect profile of ponesimod is similar to other S1P1-R modulators. While adverse events were similar between the two groups, treatment discontinuation was greater for ponesimod. The results from this study supports the efficacy superiority of ponesimod over teriflunomide in individuals with MS.

https://jamanetwork.com/journals/jamaneurology/fullarticle/2777917?resultClick=24

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis This superiority study compares the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with relapsing multiple sclerosis.